63024-30-6

Basic information

• Product Name: METHYL-2-(S)-BIPHENYL-2-AMINOPROPIONATE
• Synonyms: METHYL-2-(S)-BIPHENYL-2-AMINOPROPIONATE;(S)-METHYL 2-AMINO-3-(BIPHENYL-4-YL)PROPANOATE HYDROCHLORIDE;Methyl 4-phenyl-L-phenylalanate HCl
• CAS NO: 63024-30-6
• Molecular Formula: C₁₆H₁₇NO₂*ClH
• Molecular Weight: 255.31
• Mol File: 63024-30-6.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 418.8°C at 760 mmHg
• Flash Point: 207.1°C
• Appearance: /
• Vapor Pressure: 2.05E-07mmHg at 25°C
• CAS DataBase Reference: METHYL-2-(S)-BIPHENYL-2-AMINOPROPIONATE(CAS DataBase Reference)
• NIST Chemistry Reference: METHYL-2-(S)-BIPHENYL-2-AMINOPROPIONATE(63024-30-6)
• EPA Substance Registry System: METHYL-2-(S)-BIPHENYL-2-AMINOPROPIONATE(63024-30-6)

Safety Data

• Hazardous Substances Data: 63024-30-6(Hazardous Substances Data)

Usage

InChI:InChI=1/C16H17NO2.ClH/c1-19-16(18)15(17)11-12-7-9-14(10-8-12)13-5-3-2-4-6-13;/h2-10,15H,11,17H2,1H3;1H/t15-;/m0./s1

Upstream product

• 137255-86-8 methyl (S)-3-([1,1'-biphenyl]-4-yl)-2-((tert-butoxycarbonyl)amino)propanoate 
• 67-56-1 methanol 
• 155760-02-4 (S)-3-([1,1'-biphenyl]-4-yl)-2-aminopropanoic acid 
• 119273-61-9 N-tert-butoxycarbonyl-p-phenyl-L-phenylalanine 

Downstream Products

• 449728-95-4 (S)-2-(7-benzyloxycarbamoyl-heptanoylamino)-3-biphenyl-4-yl-propionic acid methyl ester 
• 268225-37-2 (S)-2-{2-Benzyl-3-[(1-benzyloxycarbonylamino-2-phenyl-ethyl)-hydroxy-phosphinoyl]-propionylamino}-3-biphenyl-4-yl-propionic acid 
• 660831-17-4 (2S)-[(2-biphenyl-4-yl-(1S)-1-methoxycarbonyl-ethylamino)-methyl]-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 933063-59-3 3-biphenyl-4-yl-(2S)-[(4'-trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid methyl ester 

Relevant articles and documents

4-Biphenylalanine- and 3-Phenyltyrosine-Derived Hydroxamic Acids as Inhibitors of the JumonjiC-Domain-Containing Histone Demethylase KDM4A

Overexpression of the histone lysine demethylase KDM4A, which regulates H3K9 and H3K36 methylation states, has been related to the pathology of several human cancers. We found that a previously reported hydroxamate-based histone deacetylase (HDAC) inhibitor (SW55) was also able to weakly inhibit this demethylase with an IC50value of 25.4 μm. Herein we report the synthesis and biochemical evaluations, with two orthogonal in vitro assays, of a series of derivatives of this lead structure. With extensive chemical modifications on the lead structure, also by exploiting the versatility of the radical arylation with aryldiazonium salts, we were able to increase the potency of the derivatives against KDM4A to the low-micromolar range and, more importantly, to obtain demethylase selectivity with respect to HDACs. Cell-permeable derivatives clearly showed a demethylase-inhibition-dependent antiproliferative effect against HL-60 human promyelocytic leukemia cells.

Pharmaceutical compositions, methods of preparation thereof, and methods of treatment

The present invention provides compositions, useful as pharmaceuticals, comprising 3-biphenyl-4-yl-(2S)-[(4′-trifluoromethyl-biphenyl-4-carbonyl)-amino]-propionic acid. Also disclosed are methods for preparing the compositions and methods for using the compositions.

A Simple Asymmetric Synthesis of 4-Arylphenylalanines via Palladium-Catalyzed Cross-Coupling Reaction of Arylboronic Acids with Tyrosine Triflate

-